Bonus Material-01_Restrepo_Pneumonias_CHEST_BR_2025_FINAL

Pdf Summary

This comprehensive lecture by Dr. Marcos I. Restrepo covers pneumonia, focusing on community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).<br /><br />Key points on CAP include its epidemiology, risk factors, diagnosis, treatment, and prevention. CAP remains a global health challenge with high mortality and long-term risk. Important risk factors include age, immunosuppression, chronic diseases, and recent healthcare exposures. Diagnosis can be assisted by lung ultrasound, which has high sensitivity and specificity as an alternative to chest X-ray. Severity is assessed using tools like PSI, CURB-65, and ATS/IDSA severity criteria to guide care levels.<br /><br />Treatment guidelines from ATS/IDSA (2019, updated 2025) emphasize selecting empiric antibiotics based on risk factors, microbiology, and severity, with de-escalation recommended once cultures and clinical stability allow. Shorter antibiotic courses (3-5 days) are increasingly supported for non-severe CAP. Systemic corticosteroids may benefit severe CAP patients with high inflammation but are contraindicated in influenza pneumonia. Viral-bacterial co-infection complicates treatment, influencing the use of empiric antibiotics when respiratory viruses are detected.<br /><br />For HAP/VAP, occurring after 48 hours of hospitalization or mechanical ventilation, diagnosis is challenging. Microbiologic sampling includes endotracheal aspirate and bronchoalveolar lavage; biomarkers like procalcitonin have limited utility in starting therapy but may guide discontinuation. The microbiology shows predominance of Gram-negative bacteria (Pseudomonas aeruginosa, Acinetobacter baumannii) and MRSA. Resistance is a growing concern. Empiric therapy considers MDR risk factors; anti-pseudomonal beta-lactams and MRSA coverage are standard when indicated. New antibiotics like sulbactam-durlobactam provide options against MDR Acinetobacter. Aerosolized antibiotics may assist in refractory cases.<br /><br />Prevention strategies include vaccination (influenza, pneumococcal), antimicrobial stewardship, and VAP bundles focusing on oral care and minimizing ventilation duration. Guidelines stress de-escalation of therapy and limiting antibiotic duration to reduce adverse events and resistance.<br /><br />In conclusion, pneumonia management demands integration of evolving epidemiology, diagnostics, and therapeutics with personalized treatment and preventive measures to reduce morbidity, mortality, and healthcare burden.

Meta Tag

Concept Community-Acquired Pneumonia

Concept Nosocomial Pneumonia

Concept Ventilator-Associated Pneumonia

Concept Empiric Antibiotic

Concept Microbiology

Keywords

pneumonia

community-acquired pneumonia

hospital-acquired pneumonia

ventilator-associated pneumonia

empiric antibiotics

antimicrobial stewardship

procalcitonin

lung ultrasound

MRSA

Pseudomonas aeruginosa

Community-Acquired Pneumonia

Nosocomial Pneumonia

Ventilator-Associated Pneumonia

Empiric Antibiotic

Microbiology